, Volume 17, Issue 4, pp 589–591 | Cite as

Unusual presentation of recurrent papillary thyroid microcarcinoma with neck muscles and skin dissemination

  • Alessandro Sindoni
  • Carlo Gobitti
  • Sandro Sulfaro
  • Vittorio Giacomarra
  • Eugenio BorsattiEmail author
Letter to the Editor

Dear Sir,

Papillary thyroid microcarcinoma is commonly considered to have a good prognosis. We report the case of a 47-year-old male patient, who was referred to our Institution for a papillary thyroid microcarcinoma infiltrating perithyroidal fibroadipose tissue, treated in 2006 with surgery and in 2007 with 131I-therapy (3700 MBq). He was followed up between 2007 and 2017 and was free of disease based on serum Tg and ultrasonography; then, suddenly, some pimple-like neck skin lesions appeared that were not responsive to topical therapy.

The patient underwent excision of these skin lesions, which at histopathology were found to originate from papillary thyroid carcinoma. A subsequent neck ultrasonography revealed a 9 × 4-mm nodule in the sternothyroid muscle and a 4-mm nodule in the sternocleidomastoid muscle (Fig.  1). Diagnostic 131I whole-body scan performed after recombinant human TSH (rhTSH) stimulation was negative (Fig.  2a, b), but serum Tg was detectable (16/02/2018:TSH...


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All diagnostic and therapeutic procedures performed in this study were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards.

Informed consent

Informed consent was obtained from the individual participants included in the study.


  1. 1.
    Na SJ, Yoo IR, JH O et al (2012) Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med 26:26–34CrossRefGoogle Scholar
  2. 2.
    Ozkan E, Aras G, Kucuk NO (2013) Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131I whole-body scan results. Clin Nucl Med 38:326–331CrossRefGoogle Scholar
  3. 3.
    Vural GU, Akkas BE, Ercakmak N et al (2012) Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med 37:953–959CrossRefGoogle Scholar
  4. 4.
    Fama F, Sindoni A, Cicciu M et al (2018) Preoperatively undiagnosed papillary thyroid carcinoma in patients thyroidectomized for benign multinodular goiter. Arch Endocrinol Metab 62:139–148PubMedGoogle Scholar
  5. 5.
    Ardito G, Revelli L, Giustozzi E et al (2013) Aggressive papillary thyroid microcarcinoma: prognostic factors and therapeutic strategy. Clin Nucl Med 38:25–28CrossRefGoogle Scholar
  6. 6.
    Qiu ZL, Luo QY (2009) Erector spinae metastases from differentiated thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med 34:137–140CrossRefGoogle Scholar
  7. 7.
    Mihailovic J, Stefanovic L, Stankovic R (2013) Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma. Clin Nucl Med 38:332–338CrossRefGoogle Scholar
  8. 8.
    Yazici B, Ertan Y, Oral A et al (2015) A clear cell variant of papillary thyroid microcarcinoma with lung, bone, and soft tissue metastases. Clin Nucl Med 40:885–887CrossRefGoogle Scholar
  9. 9.
    Li ZG, Lin ZC, Mu HY (2016) Polysplenia syndrome with splenic and skeletal muscle metastases from thyroid carcinoma evaluated by FDG PET/CT: case report and literature review: a care-compliant article. Medicine (Baltimore) 95:e2532CrossRefGoogle Scholar
  10. 10.
    Zhao LX, Li L, Li FL, Zhao Z (2010) Rectus abdominis muscle metastasis from papillary thyroid cancer identified by I-131 SPECT/CT. Clin Nucl Med 35:360–361CrossRefGoogle Scholar
  11. 11.
    Campennì A, Violi MA, Ruggeri RM et al (2010) Clinical usefulness of 99mTc-MIBI scintigraphy in the postsurgical evaluation of patients with differentiated thyroid cancer. Nucl Med Commun 31:274–279CrossRefGoogle Scholar
  12. 12.
    Sarma M, Sonik B, Subramanyam P et al (2015) Isolated skeletal muscle metastatic deposit in a patient with micropapillary carcinoma thyroid identified by 18F FDG PET CT. J Egypt Natl Canc Inst 27:47–50CrossRefGoogle Scholar
  13. 13.
    Yun M, Noh TW, Cho A et al (2010) Visually discernible [18F] fluorodeoxyglucose uptake in papillary thyroid microcarcinoma: a potential new risk factor. J Clin Endocrinol Metab 95:3182–3188CrossRefGoogle Scholar
  14. 14.
    Seely S (1980) Possible reasons for high resistance of muscle to cancer. Med Hypotheses 6:133–137CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2018
corrected publication 2018

Authors and Affiliations

  • Alessandro Sindoni
    • 1
  • Carlo Gobitti
    • 2
  • Sandro Sulfaro
    • 3
  • Vittorio Giacomarra
    • 4
  • Eugenio Borsatti
    • 1
    Email author
  1. 1.Nuclear Medicine UnitCRO Aviano National Cancer InstituteAvianoItaly
  2. 2.Radiotherapy UnitCRO Aviano National Cancer InstituteAvianoItaly
  3. 3.Pathology Unit“Santa Maria Degli Angeli” HospitalPordenoneItaly
  4. 4.Otorhinolaryngology Unit“Santa Maria Degli Angeli” HospitalPordenoneItaly

Personalised recommendations